Accessibility Menu

Theralase Technologies(FRA) TTX

Market Cap€30.75MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPON/A
5 YearN/A
1 YearN/A
1 MonthN/A
€0.12
+12.50%
+0.01Today

Theralase Technologies Financials at a Glance

Market Cap

€30.75MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€0.50

Net Income (TTM)

-€2.35

EPS (TTM)

-€0.01

P/E Ratio

-11.69

Dividend

€0.00

Beta (Volatility)

0.10 (Low)

Price

€0.12

Volume

142,037

Open

€0.11

Previous Close

€0.12

Daily Range

€0.11 - €0.12

52-Week Range

€0.08 - €0.23

Estimated Earnings Date

N/A

TTX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Theralase Technologies

Theralase Technologies, Inc. engages in the design, development, and manufacture of patented laser technology platforms used in bio-stimulative and bio-destructive clinical applications in patients. It operates through the Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT) segments. The ACT segment covers the research and development of photo dynamic compounds (PDCs) for the treatment of cancer. The CLT segment is responsible for the company’s medical laser business, which researches, develops, manufactures, and distributes CLT systems to healthcare practitioners predominantly for the healing of pain. The company was founded by Roger J. Dumoulin-White on August 22, 1989 and is headquartered in Toronto, Canada.

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

16

CEO

Roger J. Dumoulin-White

Website

www.theralase.com

TTX Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

-93.88%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-8.55%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

€30.75MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

295.67M

Volume

142.04K

Avg. Volume

760.242

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Theralase Technologies Performance Analysis

Theralase Technologies annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 832,15758.0%
20232023-12-31EUR 733,505-11.9%
20242024-12-31EUR 697,381-4.9%
20252025-12-31EUR 517,752-25.8%
Theralase Technologies annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR -0.0226.0%
20232023-12-31EUR -0.01-22.8%
20242024-12-31EUR -0.01-15.5%
20252025-12-31EUR -0.01-14.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€0.10

+0.7%

Gross Profit

€0.02

+0.5%

Gross Margin

21.11%

+0.7%

Market Cap

€30.75MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

€2.55

N/A

Employees

16

N/A

Net Income

-€0.66

+1.1%

EBITDA

-€0.63

+1.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€3.33

+1734.4%

Total Debt

€0.09

+0.6%

Accounts Receivable

€0.30

+2.2%

Inventory

€0.29

+0.9%

Long Term Debt

€0.02

+0.2%

Short Term Debt

€0.07

+1.4%

Return on Assets

-68.30%

+0.5%

Return on Invested Capital

-172.96%

+1.2%

Free Cash Flow

-€0.77

+1.2%

Operating Cash Flow

-€0.76

+1.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About TTX

What is the current price of Theralase Technologies?

Theralase Technologies is trading at €0.12 per share.

What is the 52-week range for Theralase Technologies?

Over the past 52 weeks, Theralase Technologies has traded between €0.08 and €0.23.

How much debt does Theralase Technologies have?

As of the most recent reporting period, Theralase Technologies reported total debt of €91.68K.

How much cash does Theralase Technologies have on hand?

Theralase Technologies reported €3.24M in cash and cash equivalents in its most recent financial results.

What is Theralase Technologies’s dividend yield?

Theralase Technologies does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services